172 related articles for article (PubMed ID: 32296512)
1. Ceftolozane-tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study.
Raby E; Naicker S; Sime FB; Manning L; Wallis SC; Pandey S; Roberts JA
Eur J Hosp Pharm; 2020 Mar; 27(e1):e84-e86. PubMed ID: 32296512
[TBL] [Abstract][Full Text] [Related]
2. Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps.
Terracciano J; Rhee EG; Walsh J
Curr Ther Res Clin Exp; 2017; 84():22-25. PubMed ID: 28761575
[TBL] [Abstract][Full Text] [Related]
3. Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy.
Jamieson C; Drummond F; Hills T; Ozolina L; Gilchrist M; Seaton RA; Santillo M; Wilkinson AS; Allwood MC
JAC Antimicrob Resist; 2021 Sep; 3(3):dlab141. PubMed ID: 34676364
[TBL] [Abstract][Full Text] [Related]
4. Temperature profiles of antibiotic-containing elastomeric infusion devices used by ambulatory care patients.
Docherty T; Montalto M; Leslie J; King K; Niblett S; Garrett T
Am J Health Syst Pharm; 2017 Jul; 74(13):992-1001. PubMed ID: 28645997
[TBL] [Abstract][Full Text] [Related]
5. Systematic review of the stability of antimicrobial agents in elastomeric devices for outpatient parenteral antimicrobial therapy services based on NHS Yellow Cover Document standards.
Jenkins A; Shanu S; Jamieson C; Santillo M
Eur J Hosp Pharm; 2022 Nov; 29(6):304-307. PubMed ID: 33990388
[TBL] [Abstract][Full Text] [Related]
6. Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis.
Elizabeth Davis S; Ham J; Hucks J; Gould A; Foster R; Ann Justo J; Nicolau DP; Bookstaver PB
Am J Health Syst Pharm; 2019 Apr; 76(8):501-504. PubMed ID: 31361864
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the stability of citrate-buffered piperacillin/tazobactam for continuous infusion when stored in two commercially available elastomeric devices for outpatient parenteral antimicrobial chemotherapy: a study compliant with the NHS Yellow Cover Document requirements.
Jamieson C; Ozolina L; Seaton RA; Gilchrist M; Hills T; Drummond F; Wilkinson AS;
Eur J Hosp Pharm; 2022 Jul; 29(4):212-216. PubMed ID: 32978220
[TBL] [Abstract][Full Text] [Related]
8. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Natesan S; Pai MP; Lodise TP
J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
[TBL] [Abstract][Full Text] [Related]
9. Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastomeric pump supporting transition of the EPOCH regimen to outpatient care.
Svirskis D; Behera S; Naidoo N; Beachman J; Raina T; Zhou Y; Berkahn L; Costello I; Gu Y
J Oncol Pharm Pract; 2019 Jun; 25(4):831-840. PubMed ID: 29540104
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices.
Chen IH; Martin EK; Nicolau DP; Kuti JL
Clin Ther; 2020 Apr; 42(4):606-613. PubMed ID: 32139176
[TBL] [Abstract][Full Text] [Related]
11. Oxygenator Impact on Ceftolozane and Tazobactam in Extracorporeal Membrane Oxygenation Circuits.
Cies JJ; Moore WS; Giliam N; Low T; Enache A; Chopra A
Pediatr Crit Care Med; 2020 Mar; 21(3):276-282. PubMed ID: 31688715
[TBL] [Abstract][Full Text] [Related]
12. Ceftolozane-tazobactam for the treatment of multidrug-resistant
Alessa MA; Almangour TA; Alhossan A; Alkholief MA; Alhokail M; Tabb DE
Am J Health Syst Pharm; 2018 May; 75(9):e184-e188. PubMed ID: 29691260
[TBL] [Abstract][Full Text] [Related]
13. Stability of antimicrobial agents in an elastomeric infusion pump used for outpatient parenteral antimicrobial therapy.
Akahane M; Enoki Y; Saiki R; Hayashi Y; Hiraoka K; Honma K; Itagaki M; Gotoda M; Shinoda K; Hanyu S; Hamamura Y; Miyajima T; Ito C; Taguchi K; Uno S; Uwamino Y; Iketani O; Hasegawa N; Matsumoto K
Int J Infect Dis; 2021 Feb; 103():464-468. PubMed ID: 33246042
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the stability of citrate-buffered flucloxacillin for injection when stored in two commercially available ambulatory elastomeric devices: INfusor LV (Baxter) and Accufuser (Woo Young Medical): a study compliant with the NHS Yellow Cover Document (YCD) requirements.
Allwood MC; Stonkute D; Wallace A; Wilkinson AS; Hills T; Jamieson C;
Eur J Hosp Pharm; 2020 Mar; 27(2):90-94. PubMed ID: 32153771
[TBL] [Abstract][Full Text] [Related]
15. Determination of total and free ceftolozane and tazobactam in human plasma and interstitial fluid by HPLC-UV.
Kratzer A; Schießer S; Matzneller P; Wulkersdorfer B; Zeitlinger M; Schlossmann J; Kees F; Dorn C
J Pharm Biomed Anal; 2019 Jan; 163():34-38. PubMed ID: 30278324
[TBL] [Abstract][Full Text] [Related]
16. [In vitro study of the flow duration of antibiotics solutions prepared in elastomeric infusion devices: effect of cold storage for 3 to 7days].
Grangeon-Chapon C; Robein-Dobremez MJ; Pin I; Trouiller P; Allenet B; Foroni L
Ann Pharm Fr; 2015 Sep; 73(5):378-90. PubMed ID: 25721763
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
18. Stability of meropenem in portable elastomeric infusion devices: which protocol should be implemented in clinical practice?
Esteban-Cartelle B; Serrano DR; Pérez Menéndez-Conde C; Vicente-Oliveros N; Álvarez-Díaz A; Abete JF; Martín-Dávila P
Microbiol Spectr; 2024 Feb; 12(2):e0206323. PubMed ID: 38230930
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection.
Bradley JS; Ang JY; Arrieta AC; Larson KB; Rizk ML; Caro L; Yang S; Yu B; Johnson MG; Rhee EG
Pediatr Infect Dis J; 2018 Nov; 37(11):1130-1136. PubMed ID: 30153232
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
